NephroGenex shares rocket after lead drug found safe for heart

(Reuters) – Shares of NephroGenex Inc shot up nearly nine-fold in premarket trading, a day after the drug developer said its lead drug was found to be safe in a cardiac safety study. The oral drug, pyridorin, is being evaluated in a late-stage study in patients with diabetic nephropathy – a chronic, degenerative kidney disease caused by diabetes, which is often accompanied by heart disease. Cardiac safety concerns have been seen with other therapies in development, the company said late on Tuesday. …
Go to Source